Prevalite (cholestyramine) NDC 0245-0036

NDC codes

FDA NDC Directory

Product NDC (as listed)0245-0036Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00245-0036Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
0245-0036-23	00245003623	231 g in 1 CAN (0245-0036-23)Marketed from Feb 1, 1996
0245-0036-42	00245003642	42 PACKET in 1 CARTON (0245-0036-42) / 5.5 g in 1 PACKET (0245-0036-89)Marketed from Feb 1, 1996
0245-0036-60	00245003660	60 PACKET in 1 CARTON (0245-0036-60) / 5.5 g in 1 PACKET (0245-0036-89)Marketed from Feb 1, 1996

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Prevalite
Generic name (nonproprietary): cholestyramine
Active ingredients: Cholestyramine — 4 g/5.5g
Dosage form: Powder, For suspension
Route: Oral
Labeler: Upsher-Smith Laboratories, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 073263
Marketing start: Feb 1, 1996
Marketing end: Oct 31, 2027
Other FDA classes: Bile-acid Binding Activity (Mechanism)
Identifiers: Product ID 0245-0036_44feb603-0970-9b63-e063-6294a90a7ce5SPL ID 44feb603-0970-9b63-e063-6294a90a7ce5SPL set ID dd434ef8-8af3-434c-a0a0-9a0b18459ba0RxCUI 848951, 1801279UNII 4B33BGI082
Pharmacologic class: Bile Acid Sequestrant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400245003623 followed by a unit qualifier and the quantity

Package 00245-0036-23. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 2, 2025.

Indications (excerpt from the label)

INDICATIONS AND USAGE 1) Prevalite ® (cholestyramine for oral suspension, USP) powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Prevalite ® (cholestyramine for oral suspension, USP) powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)